Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis

Journal of Bone and Joint Surgery

Volumn 84, Issue 8, 2002, Pages 1405-1412

  Ulrich Vinther, Michael ^a   Carmody, Emily E ^a   Goater, J Jeffrey ^a   Soøballe, Kjeld ^b   O'Keefe, Regis J ^a   Schwarz, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR 1; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; RECOMBINANT PROTEIN; TITANIUM;

ADENO ASSOCIATED VIRUS; ANIMAL TISSUE; ARTICLE; CALVARIA; COCULTURE; CONTROLLED STUDY; EXPRESSION VECTOR; FIBROBLAST; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROSTHESIS LOOSENING; SPLEEN CELL; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT;

EID: 0036704231     PISSN: 00219355     EISSN: None     Source Type: Journal    
DOI: 10.2106/00004623-200208000-00016     Document Type: Article

References (35)

1. Goldring SR, Jasty M, Roelke MS, Rourke CM, Bringhurst FR, Harris WH. Formation of a synovial-like membrane at the bone-cement interface. Its role in bone resorption and implant loosening after total hip replacement. Arthritis Rheum. 1986;29:836-42.
2. al Saffar N, Revell PA. Interleukin-1 production by activated macrophages surrounding loosened orthopaedic implants: A potential role in osteolysis. Br J Rheumatol. 1994;33:309-16.
3. Roebuck KA, Jacobs JJ, Giant TT. New horizons in orthopaedic research: Elucidation of cellular signal transduction pathways [editorial]. J Bone Joint Surg Am. 1999;81:599-602.
4. Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289:1504-8.
5. Childs LM, Paschalis EP, Xing L, Dougall WC, Anderson D, Boskey AL, Puzas JE, Rosier RN, O'Keefe RJ, Boyce BF, Schwarz EM. In vivo RANK signaling blockade using the receptor activator of NF-kappaB:Fc effectively prevents and ameliorates wear debris-induced osteolysis via osteoclast depletion without inhibiting osteogenesis. J Bone Miner Res. 2002;17:192-9.
6. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Luthy R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G, DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J, Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison W, Campbell P, Boyle WJ, et al. Osteoprotegerin: A novel secreted protein involved in the regulation of bone density. Cell. 1997;89:309-19.
7. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D, Galibert L. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390:175-9.
8. Schwarz EM, O'Keefe RJ. Breakthrough in bone: The molecular mechanism of osteoclast/osteoblast coupling revealed. Curr Opin Orthop. 2000;11:329-35.
9. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature. 1999;402:304-9.
10. Capparelll C, Kostenuik PJ, Morony S, Starnes C, Weimann B, Van G, Scully S, Qi M, Lacey DL, Dunstan CR. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. Cancer Res. 2000;60:783-7.
11. Oyajobl BO, Anderson DM, Traianedes K, Williams PJ, Yoneda T, Mundy GR. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. Cancer Res. 2001;61:2572-8.
12. Zhang J, Dai J, Qi Y, Lln DL, Smith P, Strayhorn C, Mizokami A, Fu Z, Westman J, Keller ET. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J Clin Invest. 2001;107:1235-44.
13. Goater JJ, O'Keefe RJ, Rosier RN, Puzas JE, Schwarz EM. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. J Orthop Res. 2002;20:169-73.
14. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16:348-60.
15. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH, Robbins PD. Gene therapy for rheumatic diseases. Arthritis Rheum. 1999;42:1-16.
16. Verma IM, Somia N. Gene therapy - Promises, problems and prospects. Nature. 1997;389:239-42.
17. Samulski RJ, Srivastava A, Berns KI, Muzyczka N. Rescue of adeno-associated virus from recombinant plasmids: Gene correction within the terminal repeats of AAV. Cell. 1983;33:135-43.
18. Schwarz EM. The adeno-associated virus vector for orthopaedic gene therapy. Clin Orthop. 2000;379 Suppl:S31-9.
19. Monahan PE, Samulski RJ. AAV vectors: Is clinical success on the horizon? Gene Ther. 2000;7:24-30.
20. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 1996;274:787-9.
21. Samulski RJ, Chang LS, Shenk T. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression. J Virol. 1989;63:3822-8.
22. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol. 1998;72:2224-32.
23. Goater J, Muller R, Kollias G, Firestein GS, Sanz I, O'Keefe RJ, Schwarz EM. Empirical advantages of adeno associated viral vectors in vivo gene therapy for arthritis. J Rheumatol. 2000;27:983-9.
24. Li P, Sanz I, O'Keefe RJ, Schwarz EM. NTF-kappaB regulates VCAM-1 expression on fibroblast-like synoviocytes. J Immunol. 2000;164:5990-7.
25. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Effect of anti-tumor necrosis factor-alpha gene therapy on wear debris-induced osteolysis. J Bone Joint Surg Am. 2001;83:1789-97.
26. Childs LM, Goater JJ, O'Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced osteolysis. J Bone Miner Res. 2001;16:338-47.
27. Schwarz EM, Krimpenfort P, Berns A, Verma IM, Immunological defects in mice with a targeted disruption in Bcl-3. Genes Dev. 1997;11:187-97.
28. Zhang X, Morham SG, Langenbach R, Young DA, Xing L, Boyce BF, Puzas EJ, Rosier RN, O'Keefe RJ, Schwarz EM. Evidence for a direct role of cyclooxygenase 2 in implant wear debris-induced osteolysis. J Bone Miner Res. 2001;16:660-70.
29. Boyce BF, Aufdemorte TB, Garrett IR, Yates AJ, Mundy GR. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology. 1989;125:1142-50.
30. Merkel KD, Erdmann JM, McHugh KP, Abu-Amer Y, Ross FP, Teltelbaum SL. Tumor necrosis factor-alpha mediates orthopedic implant osteolysis. Am J Pathol. 1999;154:203-10.
31. Schwarz EM, Benz EB, Lu AP, Goater JJ, Mollano AV, Rosier RN, Puzas JE, O'Keefe RJ. Quantitative small-animal surrogate to evaluate drug efficacy in preventing wear debris-induced osteolysis. J Orthop Res. 2000;18:849-55.
32. Shanbhag AS, Hasselman CT, Rubash HE. The John Charnley Award. Inhibition of wear debris mediated osteolysis in a canine total hip arthroplasty model. Clin Orthop. 1997;344:33-43.
33. Leung A, Scammell B, Lyons A, Czachur M, Gilbert J, Freedholm D, Malbecq W, Miller C, Carr A, Checkley L. Alendronate prevents periprosthetic bone loss-2 year results. Arthritis Rheum. 1999;42(Suppl):S270.
34. Ralston SH, Hacking L, Willocks L, Bruce F, Pitkeathly DA. Clinical, biochemical, and radiographic effects of aminohydroxypropylidene bisphosphonate treatment in rheumatoid arthritis. Ann Rheum Dis. 1989;48:396-9.
35. Eggelmeijer F, Papapoulos SE, van Paassen HC, Dijkmans BA, Valkema R, Westedt ML, Landman JO, Pauwels EK, Breedveld FC. Increased bone mass with pamidronate treatment in rheumatoid arthritis. Results of a three-year randomized, double-blind trial. Arthritis Rheum. 1996;39:396-402.